ThromboGenics' goal is to become a leader in the development and commercialisation of innovative drugs for the treatment of disorders of the vasculature. The Company intends to achieve this by exploiting its core expertise in cardiovascular medicine, by continuing to develop internally and in-license early stage compounds with potential in the treatment of blood vessel disorders and by continuing to advance them through the clinical development and regulatory approval process. When appropriate, the Company intends to achieve its goals in collaboration with experienced partners.